

CFW 1614

PTO/SB/21 (09-04)

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/509,693
Filing Date	09/29/2004
First Named Inventor	Dennis A. Carson
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	02307O-123910US

### ENCLOSURES (Check all that apply)

- |  |   |   |
|--|---|---|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement with PTO/SB/08<br><br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Reply to Missing Parts/ Incomplete Application<br><input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____<br><input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):<br>Cited References A7-A23; Return Postcard |
|--|---|---|

Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name Townsend and Townsend and Crew LLP

Signature

Printed name Joel G. Ackerman

Date 7/14/05

Reg. No. 24,307

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature

Typed or printed name

Anna C. Kundel


Date

7/14/05

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 023070-123910US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



On

July 14, 2005

TOWNSEND and TOWNSEND and CREW LLP

By:

Anna C. Kundel

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Dennis A. Carson, *et al.*

Application No.: 10/509,693

Filed: September 29, 2004

For: TREATMENT OF CANCER WITH  
MEFLOQUINE, ITS PURIFIED  
ENANTIOMERS, AND MEFLOQUINE  
ANALOGS

Examiner: Not Yet Assigned

Art Unit: 1614

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 1287 OG 163] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Joel G. Ackerman  
Reg. No. 24,307

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
JA:ack  
60524154 v1



Substitute for form 1449A&B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/509,693
				Filing Date	09/29/2004
				First Named Inventor	Dennis A. Carson
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	023070-123910US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	A1	US-3,953,453	04-27-1976	Grethe et al.	
	A2	US-4,507,482	03-26-1985	Bömches et al.	
	A3	US-5,278,173	01-11-1994	Davis	
	A4	US-5,476,842	12-19-1995	Rubin	
	A5	US-6,197,788 B1	03-06-2001	Fletcher et al.	
	A6	US-20020022032 A1	02-21-2002	Curry et al.	


FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
								<input type="checkbox"/>
								<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A7	AYESH et al., "Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein," <i>Biochimica et Biophysica Acta</i> , 1316:8-18 (1996)	
	A8	BUCHMAN et al., "Potential Antimalarials. (Chloro-2-phenylquinolyl-4)-α-piperidylcarbinols," Contributions from the Gates and Crellin Laboratories of Chemistry, California Institute of Technology, No. 1047, 68:2710-2714 (1946)	
	A9	CARROLL et al., "Optical Isomers of Aryl-2-piperidylmethanol Antimalarial Agents. Preparation, Optical Purity, and Absolute Stereochemistry," <i>Journal of Medicinal Chemistry</i> , 17:210-218 (1974)	
	A10	HARTMAN et al., Goodman and Gilman's "The Pharmacological Basis of Therapeutics," Ninth Edition, McGraw-Hill, 975-976	
	A11	ISON et al., "Phototoxicity of Quinoline Methanols and Other Drugs in Mice and Yeast," <i>The Journal of Investigative Dermatology</i> , 52:193-198 (1969)	
	A12	LAGNEAUX et al., "Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors," <i>British Journal of Haematology</i> , 112:344-352 (2001)	
	A13	LAN et al., "Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing," <i>Cancer Chemother Pharmacol</i> , 38:181-190 (1996)	

Examiner Signature	Date Considered
-----------------------	--------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substituted for form 1449A&B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/509,693
				Filing Date	09/29/2004
				First Named Inventor	Dennis A. Carson
				Art Unit	1614
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	02307O-123910US
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	A14	LUTZ et al., "α-Alkyl and Dialkylaminomethyl-2-Phenyl-4-Quinolinemethanols," Contribution from the Cobb Chemical Laboratory of the University of Virginia, 68:1813-1831 (1946)		
	A15	MENG et al., "Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine," <i>Arthritis &amp; Rheumatism</i> , 40:927-935 (1997)		
	A16	OHNMACHT et al., "Antimalarials. 7. Bis(trifluoromethyl)-α-(2-piperidyl)-4-quinolinemethanols," <i>Journal of Medicinal Chemistry</i> , 14:926-928 (1971)		
	A17	PINDER et al., "Antimalarials. II. <sup>1a</sup> α-(2-Piperidyl)- and α-(2-Pyridyl)-2-trifluoromethyl-4-quinolinemethanols <sup>1b</sup> ," <i>Antimalarials. II</i> , 267-269 (1968)		
	A18	ROTHER et al., "Laboratory Evaluation of the Phototoxic Potency of Quinolinemethanols," Division of Medicinal Chemistry, Walter Reed Army Institute of Research, 11:366-368 (1968)		
	A19	SHAO et al., "Mutually co-operative interactions between modulators of P-glycoprotein," <i>Biochimica et Biophysica Acta</i> , 1360:30-38 (1997)		
	A20	SCHMIDT et al., "Antimalarial Activities of Various 4-Quinolinemethanols with Special Attention to WR-142,490 (Mefloquine)," <i>Antimicrobial Agents and Chemotherapy</i> , 13:1011-1030 (1978)		
	A21	SOLARY et al., "Feasibility of Using Quinine, A Potential Multidrug Resistance-Reversing Agent, in Combination With Mitoxantrone and Cytarabine for the Treatment of Acute Leukemia," <i>Journal of Clinical Oncology</i> , 10:1730-1736 (1992)		
	A22	SOLARY et al., "Combination of Quinine as a Potential Reversing Agent With Mitoxantrone and Cytarabine for the Treatment of Acute Leukemias: A Randomized Multicenter Study," <i>Blood</i> , 88:1198-1205 (1996)		
	A23	WILSON et al. (editors), Harrison's Principles of Internal Medicine, Twelfth Edition, 1412-1601		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.